Rheumatoid Arthritis Drugs Global Market Report 2024

The rheumatoid arthritis drugs market has grown marginally in recent years. It will grow from $60.82 billion in 2023 to $61.06 billion in 2024 at a compound annual growth rate (CAGR) of 0.4%. The expansion observed in the historical period can be ascribed to several factors, including the rising prevalence of diseases, advancements in healthcare infrastructure, increased awareness and educational efforts, governmental initiatives and support, as well as strategic collaborations.

The rheumatoid arthritis drugs market is expected to see marginal growth in the next few years. It will grow to $64.86 billion in 2028 at a compound annual growth rate (CAGR) of 1.5%. The anticipated expansion during the forecast period is primarily driven by the prevailing trends in personalized medicine, the burgeoning growth of emerging markets, ongoing advancements in pipeline development, a concerted emphasis on combination therapies, and a notable rise in healthcare expenditure. Key trends expected to shape the forecast period encompass the dominant role of biological therapies, the impact of biosimilars, advancements in personalized medicine, the burgeoning growth of oral therapies, and a heightened focus on early diagnosis and intervention.

The anticipated surge in arthritis cases is poised to drive the expansion of the rheumatoid arthritis drugs market in the coming years. Rheumatoid arthritis, characterized by autoimmune and inflammatory responses causing damage to healthy cells and resulting in painful swelling, has effective treatment options in the form of drugs and self-management techniques. These interventions aim to reduce pain, improve joint flexibility, and impede the progression of the disease. Notably, recent data from the Centers for Disease Control and Prevention (CDC) highlights a significant rise in arthritis cases, with 54.4 million adults diagnosed in the United States in 2021, projected to reach 78 million by 2040. Consequently, the increasing prevalence of arthritis is expected to be a key driver for the rheumatoid arthritis drug market.

The expanding elderly population is anticipated to contribute significantly to the growth of the rheumatoid arthritis drugs market. The term "elderly population" denotes individuals aged 65 and above, relative to the working-age population (18 to 64 years old). Managing rheumatoid arthritis in the elderly presents challenges and opportunities, with newer drugs such as JAK inhibitors and targeted synthetic DMARDs offering alternative options with potentially safer profiles for this demographic. As reported by ReliefWeb in July 2022, the global population of individuals aged 65 or older is projected to increase from 10% in 2022 to 16% in 2050, reaching 94 million and comprising 23% of the total population. Hence, the growth of the elderly population is a key factor propelling the rheumatoid arthritis drugs market.

The rheumatoid arthritis drug market is witnessing a notable trend in product innovations, with companies strategically embracing new product launches to maintain and enhance their market positions. One such example is the introduction of Olokizumab by R-Pharm, a Russian high-tech pharmaceutical company, in August 2022. Olokizumab is a humanized monoclonal antibody targeting the cytokine interleukin-6, a key player in the progression of joint destruction in rheumatoid arthritis. This innovative product, similar to TNF (tumor necrosis factor), mitigates inflammatory responses, thereby reducing disease activity in many rheumatoid arthritis patients.

Major players in the rheumatoid arthritis drug market are actively engaged in pioneering solutions, such as subcutaneous injection, to gain a competitive advantage. Subcutaneous injections, also known as sub-q or SQ injections, involve delivering medication just beneath the skin. For instance, Eisai Co Ltd. and Nippon Medac Co Ltd. collaborated to launch the Metoject Subcutaneous Injection Syringe in November 2022. This product represents the first self-administrable prefilled syringe formulation of methotrexate (MTX) for rheumatoid arthritis approved in Japan. The Metoject Subcutaneous Injection Syringe is user-friendly, featuring a thin, 27-gauge needle for a more comfortable injection experience, a clear injection window, and a straightforward plunger mechanism to facilitate easy self-administration.

In October 2023, Amgen Plc, a prominent US-based biotechnology company, completed the acquisition of Horizon Therapeutic Plc for $27.8 billion. This strategic move enhances Amgen's inflammation portfolio by incorporating first-in-class, early-in-lifecycle medicines designed to treat rare inflammatory diseases. Horizon Therapeutic Plc, an Ireland-based biopharmaceutical company, specializes in providing treatments for focal segmental glomerulosclerosis, kidney transplant rejection, and rheumatoid arthritis drugs. This acquisition positions Amgen to strengthen its position in the market through a diversified and expanded product offering.

Major companies operating in the rheumatoid arthritis drugs market report are Pfizer Inc., Abbvie Inc., Amgen Inc., Novartis AG, Boehringer Ingelheim International GmbH, Eli Lilly and Company, F-Hoffmann La Roche AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Merck & Co Inc., Johnson & Johnson Inc., Bayer AG, Teva Pharmaceuticals Industries Ltd., Sun Pharmaceutical Industries Ltd., Sanofi S.A, Biogen Inc., Regeneron Pharmaceuticals Inc., Galapagos NV, Abbott Laboratories, Takeda Pharmaceutical Company Limited, Mitsubishi Tanabe Pharma Corporation, UCB S.A. Belgium., Astellas Pharma Inc., Corbus Pharmaceuticals Holdings Inc., Roche Holding AG, Daiichi Sankyo Company Limited, Chr. Hansen Holding A/S, Ipsen S.A, Mallinckrodt Pharmaceuticals, Gilead Sciences Inc.

North America was the largest region in the rheumatoid arthritis drugs market in 2023. North America is expected to be the fastest-growing region in the global rheumatoid arthritis market report during the forecast period. The regions covered in the rheumatoid arthritis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the rheumatoid arthritis drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary categories of rheumatoid arthritis pharmaceuticals consist of nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, disease-modifying antirheumatic drugs (DMARDs), biologic response modifiers (BRMs), and other pharmaceutical classifications. NSAIDs, a subset of these drugs, are utilized for alleviating inflammation, fever, and other inflammatory conditions, offering advantages over steroids by minimizing adverse effects. Administration routes include oral, parenteral, topical, and alternative methods. The distribution channels for rheumatoid arthritis drugs encompass hospital pharmacies, retail pharmacies, and online pharmacies.

The rheumatoid arthritis drugs market research report provides rheumatoid arthritis drugs market statistics, including rheumatoid arthritis drugs industry global market size, regional shares, competitors with a rheumatoid arthritis drugs market share, detailed rheumatoid arthritis drugs market segments, market trends and opportunities, and any further data you may need to thrive in the rheumatoid arthritis drugs industry. This rheumatoid arthritis drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The rheumatoid arthritis drugs market consists of sales of products such as abatacept, aceclofenac and adalimumab. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.